Research & Literature

Clinical and morphological features of fibronectin glomerulopathy: a report of ten patients from a single institution.

Chen H, Bao H, Xu F, et al.

Clinical nephrology 2015; (83(2)):93-9 doi:10.5414/cn108288.

End-Stage Kidney Disease Due to Fibrillary Glomerulonephritis and Immunotactoid Glomerulopathy - Outcomes in 66 Consecutive ANZDATA Registry Cases.

Mallett A, Tang W, Hart G, et al.

American journal of nephrology 2015; (42(3)):177-84 doi:10.1159/000440815.

Development of Potent and Selective Tissue Transglutaminase Inhibitors: Their Effect on TG2 Function and Application in Pathological Conditions.

Badarau E, Wang Z, Rathbone DL, et al.

Chemistry & biology 2015; (22(10)):1347-61.

Identification of mutations in FN1 leading to glomerulopathy with fibronectin deposits.

Ohtsubo H, Okada T, Nozu K, et al.

Pediatric nephrology (Berlin, Germany) 2016; (31(9)):1459-67 doi:10.1007/s00467-016-3368-7.

Initiation Strategies for Renal-Replacement Therapy in the Intensive Care Unit.

Gaudry S, Hajage D, Schortgen F, et al.

The New England journal of medicine 2016; (375(2)):122-33 doi:10.1056/NEJMoa1603017.

Fibronectin glomerulopathy complicated with persistent cloaca and congenital esophageal atresia: a case report and literature review.

Takii M, Suehiro T, Shima A, et al.

BMC nephrology 2017; (18(1)):288 doi:10.1186/s12882-017-0704-5.

Detection of a Splice Site Variant in a Patient with Glomerulopathy and Fibronectin Deposits.

Tsuji Y, Nozu K, Sofue T, et al.

Nephron 2018; (138(2)):166-171 doi:10.1159/000484209.

Revisiting RAAS blockade in CKD with newer potassium-binding drugs.

Georgianos PI, Agarwal R

Kidney international 2018; (93(2)):325-334 doi:10.1016/j.kint.2017.08.038.

DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Nasr SH, Vrana JA, Dasari S, et al.

Kidney international reports 2018; (3(1)):56-64 doi:10.1016/j.ekir.2017.07.017.

Chronic Kidney Disease: Detection and Evaluation.

Gaitonde DY, Cook DL, Rivera IM

American family physician 2017; (96(12)):776-783.

Timing of Renal-Replacement Therapy in Patients with Acute Kidney Injury and Sepsis.

Barbar SD, Clere-Jehl R, Bourredjem A, et al.

The New England journal of medicine 2018; (379(15)):1431-1442 doi:10.1056/NEJMoa1803213.

Fibrillary Glomerulonephritis: An Update.

Rosenstock JL, Markowitz GS

Kidney international reports 2019; (4(7)):917-922 doi:10.1016/j.ekir.2019.04.013.

A novel single amino acid deletion impairs fibronectin function and causes familial glomerulopathy with fibronectin deposits: case report of a family.

Dos Reis Monteiro MLG, Custódio FB, de Menezes Neves PDM, et al.

BMC nephrology 2019; (20(1)):322 doi:10.1186/s12882-019-1507-7.

Acute kidney injury.

Ronco C, Bellomo R, Kellum JA

Lancet (London, England) 2019; (394(10212)):1949-1964 doi:10.1016/S0140-6736(19)32563-2.

Recurrence of DNAJB9-Positive Fibrillary Glomerulonephritis After Kidney Transplantation: A Case Series.

El Ters M, Bobart SA, Cornell LD, et al.

American journal of kidney diseases : the official journal of the National Kidney Foundation 2020; (76(4)):500-510 doi:10.1053/j.ajkd.2020.01.018.

Dyskalemias in patients with acute kidney injury presenting to the emergency department are common and independent predictors of adverse outcome.

Ravioli S, Pluess E, Funk GC, et al.

International journal of clinical practice 2021; (75(1)):e13653 doi:10.1111/ijcp.13653.

Clinicopathologic Features and Outcomes in Fibronectin Glomerulopathy: A Case Series of 19 Patients.

Zhang T, Zhang W, Zuo K, Cheng Z

Frontiers in medicine 2020; (7()):439 doi:10.3389/fmed.2020.00439.

Effect of intensive blood pressure on the progression of non-diabetic chronic kidney disease at varying degrees of proteinuria.

Der Mesropian PJ, Shaikh G, Beers KH, et al.

Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2021; (69(5)):1035-1043 doi:10.1136/jim-2020-001702.

Prednisone-induced sustained remission in a patient with familial fibronectin glomerulopathy (GFND).

Goldman BI, Panner BJ, Welle SL, et al.

CEN case reports 2021; (10(4)):510-514 doi:10.1007/s13730-021-00595-w.

Donor-Derived ALECT2 Amyloidosis and Recurrent Fibrillary Glomerulonephritis in a Transplant Allograft.

Nasr SH, Chavez O, Dasari S, et al.

Kidney medicine 2021; (3(3)):433-437 doi:10.1016/j.xkme.2020.11.019.

Management of Blood Pressure in Patients With Chronic Kidney Disease Not Receiving Dialysis: Synopsis of the 2021 KDIGO Clinical Practice Guideline.

Tomson CRV, Cheung AK, Mann JFE, et al.

Annals of internal medicine 2021; (174(9)):1270-1281 doi:10.7326/M21-0834.

Management of chronic kidney disease in type 2 diabetes: screening, diagnosis and treatment goals, and recommendations.

Shubrook JH, Neumiller JJ, Wright E

Postgraduate medicine 2022; (134(4)):376-387 doi:10.1080/00325481.2021.2009726.

Bortezomib-containing regiment in treating glomerulopathy with fibronectin deposits combined with monoclonal gammopathy of undetermined significance: a case report and literature review.

Zhang W, Zhang Q, Wei X, Feng Y

Annals of translational medicine 2022; (10(6)):379 doi:10.21037/atm-22-242.

Case Report: Recurrent Deposition in Renal Allografts: A Rare Case of Fibronectin Glomerulopathy Overlooked in Native Kidneys.

Wei X, Wang X, Zhang R, et al.

Frontiers in genetics 2022; (13()):839703 doi:10.3389/fgene.2022.839703.

Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.

Yau K, Dharia A, Alrowiyti I, Cherney DZI

Kidney international reports 2022; (7(7)):1463-1476 doi:10.1016/j.ekir.2022.04.094.

Clinicopathological manifestations of coexistent monoclonal immunoglobulin deposition disease and immunotactoid glomerulopathy.

Wang Y, Yan Y, Dong B, et al.

Frontiers in medicine 2022; (9()):911998 doi:10.3389/fmed.2022.911998.

Fibrillary and immunotactoid glomerulopathies in the Hunter region: a retrospective cohort study.

Cohen AWS, Vilayur E

Internal medicine journal 2023; (53(10)):1837-1845 doi:10.1111/imj.15959.

Fibronectin glomerulopathy with monoclonal gammopathy responding to bortezomib plus dexamethasone: a case report.

Li X, Qi X, Ma Z, Huang W

BMC nephrology 2022; (23(1)):382 doi:10.1186/s12882-022-03005-0.

Genetic Counseling in Kidney Disease: A Perspective.

Stein Q, Westemeyer M, Darwish T, et al.

Kidney medicine 2023; (5(7)):100668 doi:10.1016/j.xkme.2023.100668.

Generation of an induced pluripotent stem cell line XJHi001-A from a fibronectin glomerulopathy patient carrying a heterozygous NM_212482.2(C.5888-1G > C) mutation in the FN1 gene.

She L, Li X, Bai M

Stem cell research 2023; (72()):103203 doi:10.1016/j.scr.2023.103203.

Pathologic-genomic correlation identified a novel variant in FN1 and established the diagnosis of recurrent fibronectin glomerulopathy in the kidney allograft.

Batal I, Nasr SH, Dasari S, et al.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2024; (24(3)):498-502 doi:10.1016/j.ajt.2023.10.012.

Fibronectin glomerulopathy in a kidney allograft biopsy.

Klair N, Mahmood SB, El-Rifai R, et al.

BMC nephrology 2023; (24(1)):359 doi:10.1186/s12882-023-03403-y.

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.

The lancet. Diabetes & endocrinology 2024; (12(1)):51-60 doi:10.1016/S2213-8587(23)00322-4.

Tips for Testing Adults With Suspected Genetic Kidney Disease.

Savige J

American journal of kidney diseases : the official journal of the National Kidney Foundation 2024; (83(6)):816-824 doi:10.1053/j.ajkd.2023.10.011.

A case of unexpected diagnosis of fibronectin glomerulopathy with histological features of membranoproliferative glomerulonephritis.

Hata M, Mori T, Hirose Y, et al.

BMC nephrology 2024; (25(1)):25 doi:10.1186/s12882-024-03456-7.

Association of Albuminuria With Chronic Kidney Disease Progression in Persons With Chronic Kidney Disease and Normoalbuminuria : A Cohort Study.

Verma A, Schmidt IM, Claudel S, et al.

Annals of internal medicine 2024; (177(4)):467-475 doi:10.7326/M23-2814.

Detecting and managing the patient with chronic kidney disease in primary care: A review of the latest guidelines.

Mayne KJ, Hanlon P, Lees JS

Diabetes, obesity & metabolism 2024; (26 Suppl 6()):43-54 doi:10.1111/dom.15625.

Fibronectin glomerulopathy in an elderly patient with FN1 gene mutation: a case report and literature review.

Choi JY, Kim MS, Kim Z

BMC nephrology 2024; (25(1)):309 doi:10.1186/s12882-024-03752-2.

Assessing the quality of CKD care using process quality indicators: A scoping review.

Zhou N, Chen C, Liu Y, et al.

PloS one 2024; (19(12)):e0309973 doi:10.1371/journal.pone.0309973.

[Chronic Kidney Disease: epidemiology, implications for clinical practice and equations for diagnosis].

Schaeffner E

Deutsche medizinische Wochenschrift (1946) 2025; (150(3)):77-82 doi:10.1055/a-2265-9422.

Evaluation and Management of Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2024 Clinical Practice Guideline.

Madero M, Levin A, Ahmed SB, et al.

Annals of internal medicine 2025; (178(5)):705-713 doi:10.7326/ANNALS-24-01926.

Clinicopathological features of familial fibronectin glomerulopathy caused by a splice site variant in the Fibronectin 1 gene: a case report.

Nagayama Y, Otani M, Hashimoto M, et al.

CEN case reports 2025; (14(3)):351-357 doi:10.1007/s13730-025-00987-2.

Fibronectin Glomerulopathy: A First African Case Report.

Tsighe AZ, Gebreegziabhier HG, Sharma S

Case reports in nephrology and dialysis 2025; (15(1)):125-132 doi:10.1159/000546060.

Fibrillary glomerulonephritis: an observational study of clinical-pathological features and outcomes in patients from a multi-institutional cohort.

Patrick J, Charles-Rudwick M, Quinn C, et al.

Clinical kidney journal 2025; (18(6)):sfaf166 doi:10.1093/ckj/sfaf166.

Management of hypertension in chronic kidney disease: current perspectives and therapeutic strategies.

Alsalloum MA, Albekery MA, Alhomoud IS

Frontiers in medicine 2025; (12()):1630160 doi:10.3389/fmed.2025.1630160.

The Effect of Hypervolemia Control on Proteinuria in Kidney Disease: A Prospective Interventional Study.

Kahraman ZB, Dizdar OS, Gunal AI

Journal of clinical practice and research 2024; (46(3)):234-241 doi:10.14744/cpr.2024.92387.

Fibronectin glomerulopathy caused by genetic FN1 mutation: A case report and literature review.

Shi B, Xia Y, Li K, et al.

Clinical nephrology 2026; (105(5)):352-359 doi:10.5414/CN111907.

[Glomerulopathy with fibronectin deposits caused by FN1 gene mutation: A familial case report and literature review].

Chen Q, Qin L, Luo Y, et al.

Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2025; (50(10)):1952-1960 doi:10.11817/j.issn.1672-7347.2025.240643.

Rapidly progressive pediatric fibronectin glomerulopathy driven by a novel FN1 mutation (p.Thr1917del): implications for early diagnosis and recognition of systemic involvement.

Chen X, Huang J, Chen Y, et al.

Pediatric nephrology (Berlin, Germany) 2026; (41(10)):3409-3422 doi:10.1007/s00467-026-07298-3.

Fibronectin Glomerulopathy: A Case Report of Membranoproliferative Glomerulonephritis.

Sannino A, d'Angiò P, Laurino S, et al.

Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 2026; (43(2)) doi:10.69097/43-02-2026-09.

[Progression inhibition in chronic kidney disease].

Weinmann-Menke J, Galle J

Innere Medizin (Heidelberg, Germany) 2026; (67(8)):836-842 doi:10.1007/s00108-026-02145-x.

A Novel FN1 Nucleotide Variant c.3051G>C (p.Trp1017Cys) in a Pediatric Patient with Fibronectin Glomerulopathy: Case Report and Literature Review.

Sun L, Kuang X, Wu Y, Huang W

Journal of clinical medicine 2026; (15(13)) doi:10.3390/jcm15135016.

Alport Syndrome Family Screening and Management: Experience of a Tertiary Center.

Gomes AM, Reis CF, Dias J, et al.

Kidney medicine 2026; (8(8)):101419 doi:10.1016/j.xkme.2026.101419.

Successful Control of Late-Onset Nephrotic Syndrome in FN1-Associated Fibronectin Glomerulopathy: A 17-Year Clinical Course.

Kanazawa N, Iyoda M, Abe K, et al.

Nephrology (Carlton, Vic.) 2026; (31(9)):e70273 doi:10.1111/nep.70273.